Gene mutations in myeloid neoplasms affect a number of cellular pathways, including epigenetic modification (ASXL1, DNMT3A, EZH2, IDH1, IDH2, TET2), RNA splicing (SF3B1, SRSF2, U2AF1, ZRSR2), transcriptional regulation (CEBPA, ETV6, PHF6, RUNX1, TP53, WT1), and proliferative signaling pathways (FLT3, JAK2, KRAS, NRAS). This evidence concerns the gene PHF6 and myeloid neoplasm.